160 related articles for article (PubMed ID: 36692657)
21. Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
Chou R; Dana T; Brent GA; Goldner W; Haymart M; Leung AM; Ringel MD; Sosa JA
Thyroid; 2022 Jun; 32(6):613-639. PubMed ID: 35412871
[No Abstract] [Full Text] [Related]
22. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
23. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
[TBL] [Abstract][Full Text] [Related]
24. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
25. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
26. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
27. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
[TBL] [Abstract][Full Text] [Related]
28. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer.
Redlich A; Luster M; Lorenz K; Lessel L; Rohrer TR; Schmid KW; Frühwald MC; Vorwerk P; Kuhlen M
J Clin Endocrinol Metab; 2022 Jan; 107(1):e165-e177. PubMed ID: 34415989
[TBL] [Abstract][Full Text] [Related]
29. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer.
Klain M; Zampella E; Manganelli M; Gaudieri V; Nappi C; D'Antonio A; Piscopo L; Volpe F; Pace L; Schlumberger M; Cuocolo A
Endocrine; 2021 Feb; 71(2):378-384. PubMed ID: 32529282
[TBL] [Abstract][Full Text] [Related]
30. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
31. EFFECT OF POST-SURGICAL RAI THERAPY ON PARATHYROID FUNCTION IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
Zhang A; Li P; Liu Q; Peng S; Huang G; Song S
Endocr Pract; 2020 Apr; 26(4):416-422. PubMed ID: 31968192
[No Abstract] [Full Text] [Related]
32. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.
Zhang X; Higuchi T; Tomonaga H; Lamid-Ochir O; Bhattarai A; Nguyen-Thu H; Taketomi-Takahashi A; Hirasawa H; Tsushima Y
Nucl Med Commun; 2020 Apr; 41(4):350-355. PubMed ID: 32032192
[TBL] [Abstract][Full Text] [Related]
33. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma.
Signore A; Lauri C; Di Paolo A; Stati V; Santolamazza G; Capriotti G; Prosperi D; Tofani A; Valabrega S; Campagna G
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296937
[TBL] [Abstract][Full Text] [Related]
34. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
35. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
[TBL] [Abstract][Full Text] [Related]
36. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
37. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
[TBL] [Abstract][Full Text] [Related]
38. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
39. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
40. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
